Robert Jenkins

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy
    Tohru Nakagawa
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 3:e2318. 2008
  2. pmc Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy
    Nicholas Erho
    Research and Development, GenomeDx Biosciences, Vancouver, British Columbia, Canada
    PLoS ONE 8:e66855. 2013
  3. doi request reprint Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer
    Aaron S Mansfield
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Clin Pathol 139:144-50. 2013
  4. pmc A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation
    Robert B Jenkins
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Nat Genet 44:1122-5. 2012
  5. pmc Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development
    Abra G Brisbin
    Department of Health Sciences Research, Mayo Clinic, Rochester, USA
    BMC Med Genet 12:156. 2011
  6. pmc Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform
    Monica M Reinholz
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St SW, Rochester, Minnesota 55905, USA
    BMC Med Genomics 3:60. 2010
  7. ncbi request reprint A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma
    Robert B Jenkins
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 66:9852-61. 2006
  8. pmc Distinct germ line polymorphisms underlie glioma morphologic heterogeneity
    Robert B Jenkins
    Division of Experimental Pathology, Mayo Clinic, Rochester, MN, USA
    Cancer Genet 204:13-8. 2011
  9. ncbi request reprint Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831
    Patrick C Roche
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    J Natl Cancer Inst 94:855-7. 2002
  10. ncbi request reprint HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Mayo Clin Proc 77:148-54. 2002

Research Grants

Detail Information

Publications77

  1. pmc A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy
    Tohru Nakagawa
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 3:e2318. 2008
    ..We hypothesized that an expression biomarker panel can predict which men with a rising PSA would benefit from further therapy...
  2. pmc Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy
    Nicholas Erho
    Research and Development, GenomeDx Biosciences, Vancouver, British Columbia, Canada
    PLoS ONE 8:e66855. 2013
    ..We hypothesize that a genomic expression signature detected in the primary tumor represents true biological potential of aggressive disease and provides improved prediction of early prostate cancer metastasis...
  3. doi request reprint Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer
    Aaron S Mansfield
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Clin Pathol 139:144-50. 2013
    ..Using a cohort of difficult specimens, we observed less than 95% concordance between FISH and DISH. DISH may underestimate the HER2/chromosome 17 ratio, or FISH may overestimate this ratio...
  4. pmc A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation
    Robert B Jenkins
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Nat Genet 44:1122-5. 2012
    ..16-6.66, P=4.7×10(-12) to 2.2×10(-8)) but not for astrocytomas with wild-type IDH1 and IDH2 (smallest P=0.26). The conserved sequence block that includes rs55705857 is consistently modeled as a microRNA...
  5. pmc Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development
    Abra G Brisbin
    Department of Health Sciences Research, Mayo Clinic, Rochester, USA
    BMC Med Genet 12:156. 2011
    ..However, the abundance of associations around 128 Mb on chromosome 8 could mask the appearance of a weaker, but important, association elsewhere on 8q24...
  6. pmc Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform
    Monica M Reinholz
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St SW, Rochester, Minnesota 55905, USA
    BMC Med Genomics 3:60. 2010
    ..5K) and 24,526-gene panel (24K) platforms at differentiating nine human epidermal growth factor receptor 2- positive (HER2+) and 11 HER2-negative (HER2-) paraffin-embedded breast tumors...
  7. ncbi request reprint A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma
    Robert B Jenkins
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 66:9852-61. 2006
    ..Like combined 1p/19q deletion, the 1;19 translocation is associated with superior OS and progression-free survival in low-grade glioma patients...
  8. pmc Distinct germ line polymorphisms underlie glioma morphologic heterogeneity
    Robert B Jenkins
    Division of Experimental Pathology, Mayo Clinic, Rochester, MN, USA
    Cancer Genet 204:13-8. 2011
    ..77, P = 2.6 × 10(-9)). These observations generate hypotheses concerning the possible mechanisms by which specific SNPs (or alterations in linkage disequilibrium with such SNPs) are associated with glioma development...
  9. ncbi request reprint Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831
    Patrick C Roche
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    J Natl Cancer Inst 94:855-7. 2002
    ..The concordance for central HercepTest and central FISH assays was 92%. The poor concordance (74%) between local and central testing for HER2 status has led to modifications in the eligibility criteria for N9831...
  10. ncbi request reprint HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Mayo Clin Proc 77:148-54. 2002
    ..To evaluate amplification of the HER-2/neu gene by fluorescence ir situ hybridization (FISH) in tumors with weakly positive (2+) immunohistochemical staining...
  11. ncbi request reprint Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study
    Fausto J Rodriguez
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Surg Pathol 31:351-62. 2007
    ....
  12. pmc Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy
    Judith A Gilbert
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Mol Cancer Ther 7:944-51. 2008
    ....
  13. ncbi request reprint Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines
    Mark E Law
    Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Genet Cytogenet 160:1-14. 2005
    ..33. Cell lines A172 and U87 contain 1p and 19q deletions similar to those found in sporadic gliomas and will be useful cellular reagents for evaluating the function of putative 1p and 19q glioma tumor suppressor genes...
  14. ncbi request reprint Central neurocytoma: management recommendations based on a 35-year experience
    James L Leenstra
    Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 67:1145-54. 2007
    ..METHODS AND MATErials: The data from 45 patients with central neurocytomas diagnosed between 1971 and 2003 were retrospectively evaluated. Various combinations of surgery, radiotherapy (RT), and chemotherapy had been used for treatment...
  15. ncbi request reprint Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response
    Monica M Reinholz
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    Lancet Oncol 10:267-77. 2009
    ..A better understanding of how polysomy 17 affects gene-copy number and protein expression will help to select patients who will respond to therapies targeting ERBB2 and other protein products of chromosome 17 loci...
  16. ncbi request reprint Microsatellite instability in hereditary and sporadic breast cancers
    Camilo Adem
    1Division of Laboratory Genetics, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Int J Cancer 107:580-2. 2003
    ..Mismatch repair gene mutations may be secondary random events in breast cancer progression...
  17. ncbi request reprint Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer
    Norihiko Tsuchiya
    Department of Urology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Genes Chromosomes Cancer 34:363-71. 2002
    ..These data suggest that loss of 8p22 is associated with a poor prognosis, specifically when it is accompanied by AI of 8q24 in pT(2)N(0)M(0) prostate cancer...
  18. ncbi request reprint Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities
    Jan C Buckner
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 21:251-5. 2003
    ....
  19. pmc Characterization and gene expression profiling in glioma cell lines with deletion of chromosome 19 before and after microcell-mediated restoration of normal human chromosome 19
    Kristen L Drucker
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Genes Chromosomes Cancer 48:854-64. 2009
    ..This suggests that one or more of these candidates may play a role in glioma formation or progression...
  20. pmc Interphase cytogenetics for 1p19q and t(1;19)(q10;p10) may distinguish prognostically relevant subgroups in extraventricular neurocytoma
    Fausto J Rodriguez
    Department of Laboratory Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Brain Pathol 19:623-9. 2009
    ..5 to 5.5 years after first resection. These results suggest that 1p19q loss and t(1;19) occur in a subset of EVN, and may be associated with aggressive histology in these tumors...
  21. pmc Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes
    David P Steensma
    Mayo Clinic, Rochester, MN 55905, USA
    Cancer Res 69:7518-23. 2009
    ..These data support involvement of IER3 in the pathobiology of MDS...
  22. doi request reprint Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402
    Caterina Giannini
    Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Brain Pathol 18:360-9. 2008
    ..3 years in RT group. These findings suggest that classic oligodendroglial morphology combined with 1p 19q deletion may in the future be predictive of chemotherapeutic response and survival...
  23. doi request reprint Ependymal tumors with sarcomatous change ("ependymosarcoma"): a clinicopathologic and molecular cytogenetic study
    Fausto J Rodriguez
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Surg Pathol 32:699-709. 2008
    ..Although rare, ependymal neoplasms must be included among the gliomas prone to undergo sarcomatous change and we propose the term "ependymosarcoma" for these tumors...
  24. ncbi request reprint Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252
    Edith A Perez
    Mayo Clinic and Mayo Foundation, Jacksonville, FL 32224, USA
    Clin Breast Cancer 6:425-32. 2005
    ..The efficacy and tolerability of 2 different schedules of paclitaxel/carboplatin/trastuzumab for HER2-overexpressing metastatic breast cancer (MBC) were evaluated in this parallel multicenter phase II trial...
  25. ncbi request reprint Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response
    Kurt A Jaeckle
    Mayo Clinic, Rochester, NY, USA
    J Clin Oncol 24:1246-52. 2006
    ....
  26. ncbi request reprint Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression
    Junqi Qian
    Department of Laboratory Medicine and Pathology, Section of Biostatistics, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Mod Pathol 15:35-44. 2002
    ....
  27. ncbi request reprint HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 24:3032-8. 2006
    ..To evaluate concordance between local and central laboratory HER2 testing results in patients from the North Central Cancer Treatment Group (NCCTG) N9831 adjuvant trial of trastuzumab...
  28. pmc A chromosomal region 7p11.2 transcript map: its development and application to the study of EGFR amplicons in glioblastoma
    Greg D Eley
    Department of Laboratory Medicine and Pathology and Tumor Biology Program, Mayo Clinic, Rochester, MN 55905, USA
    Neuro Oncol 4:86-94. 2002
    ..2 genes that can be coamplified and overexpressed with EGFR. Furthermore, these results are consistent with EGFR amplicons retaining the same organization as the native chromosome 7p11.2 region from which they are derived...
  29. ncbi request reprint Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study
    Evanthia Galanis
    Mayo Clinic and Mayo Foundation, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:5294-304. 2005
    ..Temsirolimus (CCI-779) is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR) and represents a rational therapeutic target against glioblastoma multiforme (GBM)...
  30. pmc C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial
    Edith A Perez
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 29:651-9. 2011
    ....
  31. doi request reprint CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma
    William R Sukov
    Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Hum Pathol 40:1296-303. 2009
    ....
  32. pmc HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial
    Edith A Perez
    Serene M and Frances C Durling Professor of Medicine, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 28:4307-15. 2010
    ....
  33. pmc Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes
    Fausto J Rodriguez
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Neuropathol Exp Neurol 67:1194-204. 2008
    ..In summary, we have identified a molecular signature that distinguishes NF1-PA from S-PA and found that ALDH1L1 underexpression is associated with aggressive histology and/or biologic behavior...
  34. pmc Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177
    Paul D Brown
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 26:5603-9. 2008
    ..Erlotinib, a selective EGFR inhibitor, was combined with temozolomide (TMZ) and radiotherapy (RT) in a phase I/II trial...
  35. pmc Ectopic low-grade adrenocortical carcinoma in the spinal region: immunohistochemical and molecular cytogenetic study of a pediatric case
    Fausto J Rodriguez
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Surg Pathol 33:142-8. 2009
    ..This report demonstrates that ectopic adrenocortical tumors in the nervous system may exhibit clinicopathologic and cytogenetic features suggestive of adrenocortical carcinoma...
  36. ncbi request reprint Regulation of expression of the early growth response gene-1 (EGR-1) in malignant and benign cells of the prostate
    Gloria R Mora
    Department of Urology Research, Mayo Clinic, Rochester, Minnesota, USA
    Prostate 63:198-207. 2005
    ..This study provides insight into the mechanism(s) that regulate EGR-1 expression and activity in malignant and benign prostate cells...
  37. ncbi request reprint Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas
    Ping Yang
    Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Cancer 103:2363-72. 2005
    ..The authors have previously described a 150-kilobase minimal deletion region in gliomas that maps to 19q13.33 and contains 3 novel candidate genes (GLTSCR1, EHD2, and GLTSCR2)...
  38. ncbi request reprint Risk of cancer among relatives of patients with glioma
    Brian P O'Neill
    Department of Neurology, and the Mayo Clinic Cancer Center, Rochester Minnesota 55905, USA
    Cancer Epidemiol Biomarkers Prev 11:921-4. 2002
    ..Our results do not support the hypothesis of a familial aggregation of glioma indicative of a glioma susceptibility gene...
  39. pmc Functional and clinical significance of variants localized to 8q24 in colon cancer
    Mine S Cicek
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street Southwest, 920 Hilton Building, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 18:2492-500. 2009
    ..Finally, these risk alleles do not seem to be associated with survival...
  40. pmc Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study
    Fausto J Rodriguez
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 113:2779-89. 2008
    ..Glioblastomas exhibit a remarkable tendency toward morphologic diversity. Although rare, pseudoepithelial components (adenoid or epithelioid) or true epithelial differentiation may occur, posing a significant diagnostic challenge...
  41. pmc Genetics in glioma: lessons learned from genome-wide association studies
    Beatrice Melin
    aDepartment of Radiation Sciences, Oncology, Umea University, Sweden bDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester Minnesota, USA
    Curr Opin Neurol 26:688-92. 2013
    ..The purpose of this review is to describe the recent knowledge gathered from the identification of seven genomic regions that have been linked to the risk of developing malignant glioma...
  42. ncbi request reprint Prostate cancer cells use genetic and epigenetic mechanisms for progression to androgen independence
    Horacio Murillo
    Urology Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Genes Chromosomes Cancer 45:702-16. 2006
    ..This article contains Supplementary Material available at http://www.interscience.wiley.com/jpages/1045-2257/suppmat...
  43. ncbi request reprint Cytogenetic and molecular cytogenetic findings in dedifferentiated liposarcoma with neural-like whorling pattern and metaplastic bone formation
    Ricardo S Macarenco
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street NW, Rochester, MN 55905, USA
    Cancer Genet Cytogenet 172:147-50. 2007
    ..The specific cytogenetics and molecular determinants of these peculiar morphologic findings, however, remain unknown...
  44. ncbi request reprint Recent advances in the molecular genetics of primary gliomas
    Gaspar J Kitange
    Division of Laboratory Genetics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Opin Oncol 15:197-203. 2003
    ..The purpose of this review is to summarize some of the most important recently published findings on the molecular genetics of primary gliomas...
  45. ncbi request reprint Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival
    John C Cheville
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 95:1028-36. 2002
    ..The objective of this study was to examine the clinical and pathologic features of metastatic prostate carcinoma to bone in a large cohort of men, and the associations of these features with outcome...
  46. pmc Epigenetic changes in gliomas
    Rebecca Burgess
    Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Biol Ther 7:1326-34. 2008
    ..We expect that novel therapies will be developed to counter epigenetic changes in this deadly disease...
  47. ncbi request reprint TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors
    Colleen S Sinclair
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Cancer Res 62:3587-91. 2002
    ..TBX2 was determined to be preferentially amplified and overexpressed in BRCA1 and BRCA2 mutant tumors, whereas RPS6KB1 was not, suggesting a role for TBX2 amplification in the development of BRCA1- and BRCA2-associated breast tumors...
  48. ncbi request reprint Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas
    Gaspar Kitange
    Division of Laboratory Genetics, Mayo Clinic, Rochester, Minnesota, USA
    Genes Chromosomes Cancer 42:68-77. 2005
    ..In addition, our findings support the hypotheses that oligodendroglioma can be classified into several groups by CGHa analysis and that specific alterations in genetic dosage may have biologic or clinical significance...
  49. doi request reprint Identification of novel HMGA2 fusion sequences in lipoma: evidence that deletion of let-7 miRNA consensus binding site 1 in the HMGA2 3' UTR is not critical for HMGA2 transcriptional upregulation
    Xiaoke Wang
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Genes Chromosomes Cancer 48:673-8. 2009
    ....
  50. ncbi request reprint Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining
    Jason T Lewis
    Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    Am J Clin Pathol 124:273-81. 2005
    ..In the nonamplified cases, 17 (94%) showed no amplification in repeated FISH. Significant intratumoral heterogeneity and minimal (low-level) HER-2 amplification account for many breast cancers with 2+ HER-2 protein expression...
  51. ncbi request reprint Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia
    Tait D Shanafelt
    Mayo Clinic College of Medicine, Department of Internal Medicine, Division of Hematology, Rochester, MN 55905, USA
    J Clin Oncol 24:4634-41. 2006
    ..There are minimal prospective data on the clinical utility of the widely used hierarchical FISH prognostic categories in patients with newly diagnosed early-stage CLL or the frequency of clonal evolution as determined by interphase FISH...
  52. ncbi request reprint Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers
    Camilo Adem
    Division of Laboratory Genetics, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cancer 97:1-11. 2003
    ....
  53. ncbi request reprint Cytogenetic and molecular cytogenetic findings of intimal sarcoma
    Hongying Zhang
    Division of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Genet Cytogenet 179:146-9. 2007
    ..Further studies are needed to determine whether the cytogenetic abnormalities found in this case are recurrent events for this poorly characterized malignancy...
  54. ncbi request reprint A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine
    Kevin C Halling
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, MN, USA
    J Urol 167:2001-6. 2002
    ..We determine the sensitivity and specificity of various assays for the detection of urothelial carcinoma...
  55. ncbi request reprint Cytogenetic and molecular genetic findings in dedifferentiated liposarcoma with neural-like whorling pattern and metaplastic bone formation
    Ricardo S Macarenco
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Genet Cytogenet 171:126-9. 2006
    ..However, the specific cytogenetic and molecular determinants of these peculiar morphologic findings remain unknown...
  56. pmc Mapping and gene expression profile of the minimally overrepresented 8q24 region in prostate cancer
    Norihiko Tsuchiya
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Pathol 160:1799-806. 2002
    ..These seven genes as well as c-myc are candidate target genes within the overrepresented 8q24 region and their overexpression may be associated with prostate cancer progression...
  57. ncbi request reprint BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice
    Darren J Baker
    1 Departments of Pediatric and Adolescent Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA 2 Departments of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Nat Genet 36:744-9. 2004
    ..Natural aging of wild-type mice is marked by decreased expression of BubR1 in multiple tissues, including testis and ovary. These results suggest a role for BubR1 in regulating aging and infertility...
  58. ncbi request reprint ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers
    Camilo Adem
    Division of Laboratory Genetics, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Genes Chromosomes Cancer 41:1-11. 2004
    ....
  59. pmc Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas
    Aaron M Bender
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 70:3557-65. 2010
    ..Together, these results indicate that SB-insertional mutagenesis can identify high-grade astrocytoma-associated genes and they imply an important role for CSF1 in the development of these tumors...
  60. ncbi request reprint A class I transgene reveals regulatory events on chromosome 1 marking peripheral T cell differentiation and memory
    Cari Roark Sloma
    Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Immunol 174:7564-72. 2005
    ..These findings suggest a change in chromatin structure at the transgene integration site as cells progress from a naive to a primed/memory differentiation state...
  61. ncbi request reprint MGMT immunohistochemical expression and promoter methylation in human glioblastoma
    Fausto J Rodriguez
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    Appl Immunohistochem Mol Morphol 16:59-65. 2008
    ..This study underscores some of the difficulties in applying immunohistochemistry to assess MGMT expression...
  62. ncbi request reprint Clonal cytogenetic abnormalities in Erdheim-Chester disease
    Eneida F Vencio
    Division of Anatomic Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Surg Pathol 31:319-21. 2007
    ..However, additional studies are warranted to confirm whether the chromosomal abnormalities found in this case represent recurrent cytogenetic events...
  63. ncbi request reprint Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance
    Kenneth D Aldape
    Department of Pathology and Brain Tumor Center, UT MD Anderson Cancer Center, Houston, Texas, USA
    J Neuropathol Exp Neurol 63:700-7. 2004
    ....
  64. ncbi request reprint Myxoinflammatory fibroblastic sarcoma showing t(2;6)(q31;p21.3) as a sole cytogenetic abnormality
    Cristiane M Ida
    Division of Anatomic Pathology, Hospital das Clinicas C M I, Sao Paulo University School of Medicine, Sao Paulo, SP, Brazil
    Cancer Genet Cytogenet 177:139-42. 2007
    ..3) as the only cytogenetic abnormality. This finding is distinct from the two cases previously reported. Additional studies are needed to verify whether any of these chromosome rearrangements are involved recurrently in MIFS...
  65. pmc Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade astrocytomas
    Hiroko Kuriyama
    The Preuss Laboratory for Molecular Neuro Oncology, Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 4:179-86. 2002
    ....
  66. ncbi request reprint Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma
    Eric C Burton
    Department of Neurological Surgery, University of California, San Francisco 94143, USA
    Cancer Res 62:6205-10. 2002
    ..Loss of 19q may be a marker of long-term survival...
  67. ncbi request reprint Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
    ..We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer...
  68. ncbi request reprint The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors
    J Matthew McDonald
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:1468-77. 2005
    ..The authors sought to determine whether histology was an equivalent or superior predictor of outcome compared with 1p/19q status in 131 patients with AO tumors...
  69. ncbi request reprint Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features
    Martin J van den Bent
    Department of Neurooncology, Erasmus University Medical Center Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer 97:1276-84. 2003
    ..The authors investigated the correlation between genetic and clinical characteristics of OD in 33 patients who received chemotherapy with procarbazine, lomustine, and vincristine for recurrent disease after receiving radiotherapy...
  70. pmc Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study
    Ricardo S Macarenco
    CIPAX, Medicina Diagnostica, Sao Jose dos Campos, Sao Paulo, Brazil
    Mod Pathol 21:1168-75. 2008
    ..Immunoexpression of epidermal growth factor receptor in salivary gland-type lung carcinomas is not related to epidermal growth factor receptor gene copy number or mutational status...
  71. ncbi request reprint Prevalence of 9p21 deletions in UK melanoma families
    Sushila H Mistry
    Genetic Epidemiology Division, Cancer Research UK Clinical Centre in Leeds, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Genes Chromosomes Cancer 44:292-300. 2005
    ..Deletions at 9p21 are rare and explain only a small proportion of melanoma susceptibility. This study is the first to comprehensively exclude deletions in melanoma-prone families with no previously identified CDKN2A mutations...
  72. ncbi request reprint YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma
    Christopher E Pelloski
    Department of Radiation Oncology, Neuro Oncology, and Pathology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:3326-34. 2005
    ..Here we test these findings in a larger series of patients with glioblastoma, and in particular, determine if tumor YKL-40 expression is associated with radiation response...
  73. ncbi request reprint Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion
    Carlise R Bethel
    Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Baltimore, MD, USA
    Cancer Res 66:10683-90. 2006
    ..Monoallelic deletions on chromosome 8p are associated with more advanced invasive and aggressive disease...
  74. pmc Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis
    Bora Gurel
    Department of Pathology, The Johns Hopkins University, School of Medicine, Baltimore, MD 21231, USA
    Mod Pathol 21:1156-67. 2008
    ....
  75. ncbi request reprint High-risk lesions in high-risk women: a high-risk formalin-based biology!
    Camilo Adem
    J Clin Oncol 22:1159-61; author reply 1161-2. 2004
  76. ncbi request reprint Novel PLA2G4C polymorphism as a molecular diagnostic assay for 19q loss in human gliomas
    Christian Hartmann
    Molecular Neuro oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Charlestown 02129, USA
    Brain Pathol 12:178-82. 2002
    ..These characteristics suggest that the PLA2G4C polymorphism will be a convenient and practical assay for clinical and research evaluation of 19q status in human gliomas...
  77. ncbi request reprint Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors
    Eric C Burton
    Department of Pathology, University of California, San Francisco, San Francisco, California 94143, USA
    Clin Cancer Res 8:180-7. 2002
    ..Only 2-5% of patients originally diagnosed with GBM will survive > or = 3 years. Whether tumors from these long-term survivors (LTSs) exhibit molecular genetic differences compared with typical GBM survivors is not known...

Research Grants2

  1. GENETIC AND BIOLOGIC STUDIES OF 1P AND 19Q IN GLIOMAS
    Robert Jenkins; Fiscal Year: 2000
    ..abstract_text> ..
  2. GENETIC AND BIOLOGIC STUDIES OF 1P AND 19Q IN GLIOMAS
    Robert Jenkins; Fiscal Year: 2001
    ..abstract_text> ..